Oncology

HER2+ Breast Cancer

Advertisement

Expert Perspectives in HER2+ Breast Cancer to Cover Key Topics in HER2+ Breast Cancer Treatment

expert perspectives by Ian Krop, MD, PhD; Joseph A. Sparano, MD, FACP; Sara M. Tolaney, MD, MPH

Overview

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. Expert Perspectives in HER2+ Breast Cancer will feature community-selected experts and topics that we hope you will find of value in your clinical practice.


VIEW THE TOPICS 

Expert Roundtables 

  • Advances in the Treatment of HER2+ Breast Cancer
  • Current and Future Management of HER2+ Metastatic Breast Cancer
  • Increasing Survival in Patients With HER2+ Breast Cancer
  • Optimizing the Approach to Early-Stage HER2+ Breast Cancer

Clinical Topic Updates 

  • Clinical Roundup: HER2+ Disease at Recent Breast Cancer Conference 
  • Helping Patients Receive the Full Course of Treatment to Maximize the Benefits of the Breast Cancer Treatment Regimen 
  • Recent Developments in HER2-Targeted Therapy
  • The Importance of Next-Generation Sequencing in Guiding Therapy Selection

Patient Care Perspectives 

  • Early HER2+ Breast Cancer: How Should Pathological Responses to Neoadjuvant Therapy and Surgery Guide Decisions About Adjuvant Treatment?
  • HER2+ Breast Cancer: Discussing Treatment Options in Early, Advanced, and Metastatic Settings 
  • Identifying Candidates for Neoadjuvant or Adjuvant Anti-HER2 Therapy 
  • Prognostic Indicators in Early-Stage HER2+ Breast Cancer

Ian Krop, MD, PhD

Professor of Internal Medicine, Section of Medical Oncology
Associate Cancer Center Director, Clinical Research
Chief Clinical Research Officer
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Joseph A. Sparano, MD, FACP

Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Chief, Division of Hematology and Medical Oncology
Deputy Director
The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor, Department of Medicine
Harvard Medical School
Boston, MA

Advertisement